News
![](/upload/iblock/23d/23d2694e90ca35fd84dba3674731caae.jpg)
Press Center
![](/upload/resize_cache/iblock/c5c/140_80_2/c5cbc64b68d97023095f9529b7ffe54d.jpg)
10.10.2017
Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.
More
Topics Petrovax Pharm